Ursprung des Netzwerks ersten Grades von Dawn Schottlandt
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Dawn Schottlandt
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| PROCTER & GAMBLE COMPANY | Household/Personal Care | Corporate Officer/Principal | |
Coley Pharmaceutical Group, Inc.
 Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Pharmaceuticals: Major | Corporate Officer/Principal | |
| AURA BIOSCIENCES, INC. | Biotechnology | Human Resources Officer | |
| George Washington University | College/University | Undergraduate Degree | |
| University of New Hampshire | College/University | Undergraduate Degree | |
| Cambridge College | College/University | Graduate Degree | |
| MediVector, Inc. | General Counsel | ||
Amgen Canada, Inc.
 Amgen Canada, Inc. BiotechnologyHealth Technology Amgen Canada, Inc. operates as a biotechnology company. The company was founded in 1991 and is headquartered in Mississauga, Canada. | Biotechnology | Corporate Officer/Principal | |
| KARYOPHARM THERAPEUTICS INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Biotechnology | General Counsel | |
| University of Rochester Simon Business School | College/University | Masters Business Admin | |
| PULMATRIX, INC. | Pharmaceuticals: Major | Director/Board Member | |
| STEALTH BIOTHERAPEUTICS CORP | Biotechnology | Corporate Officer/Principal | |
| Ignition Insights LLC | Founder |
Statistik
International
| Vereinigte Staaten | 16 |
| Kanada | 2 |
Sektoral
| Health Technology | 10 |
| Consumer Services | 5 |
| Consumer Non-Durables | 2 |
Operativ
| Corporate Officer/Principal | 9 |
| General Counsel | 3 |
| Undergraduate Degree | 2 |
| Human Resources Officer | 2 |
| Masters Business Admin | 1 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Anand Varadan | 9 |
| David H. Schubert | 7 |
| Joseph Lyons | 3 |
- Börse
- Insiders
- Dawn Schottlandt
- Unternehmensverbindungen